Advertisement

Article | 2026 Retina Society Meeting

Avacincaptad Pegol and Anti-VEGF in Real-World Practice

An IRIS Registry analysis of more than 13,000 eyes found that concomitant anti-VEGF use for nAMD or CNV did not substantially alter complement inhibitor treatment.

By: Jim Gallagher, senior managing editor
Retinal Physician September 26, 2026
5 Key Takeaways

  • 1

    An analysis of the IRIS Registry included 13,391 eyes from 10,181 patients aged 50 and older receiving avacincaptad pegol.

  • 2

    Concomitant anti-VEGF therapy was used in 22.7% of eyes during follow-up, with 78.5% receiving it on the same day or within 60 days of avacincaptad pegol.

  • 3

    The average number of avacincaptad pegol injections was 3.9 for eyes receiving anti-VEGF and 3.6 for those not receiving it.

  • 4

    Discontinuation rates were 10.8% for eyes receiving anti-VEGF and 6.7% for those not receiving it, with switching to pegcetacoplan being uncommon.

  • 5

    Treatment-emergent adverse events were reported in 3.8% of eyes with anti-VEGF and 2.6% without, with CNV and nAMD being the most common adverse events.